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ABSTRACT
Objective: To evaluate, across a spectrum of
diseases, how often surrogate outcomes are used as a
basis for drug approvals by the US Food and Drug
Administration (FDA), and whether and how the
rationale for using treatment effects on surrogates as
predictors of treatment effects on patient-centred
outcomes is discussed.
Study design and setting: We used the Drugs@FDA
website to identify drug approvals produced from 2003
to 2012 by the FDA. We focused on four diseases
(chronic obstructive pulmonary disease (COPD), type 1
or 2 diabetes, glaucoma and osteoporosis) for which
surrogates are commonly used in trials. We reviewed
the drug labels and medical reviews to provide
empirical evidence on how surrogate outcomes are
handled by the FDA.
Results: Of 1043 approvals screened, 58 (6%) were
for the four diseases of interest. Most drugs for COPD
(7/9, 78%), diabetes (26/26, 100%) and glaucoma
(9/9, 100%) were approved based on surrogates while
for osteoporosis, most drugs (10/14, 71%) were also
approved for patient-centred outcomes (fractures).
The rationale for using surrogates was discussed in 11
of the 43 (26%) drug approvals based on surrogates.
In these drug approvals, we found drug approvals for
diabetes are more likely than the other examined
conditions to contain a discussion of trial evidence
demonstrating that treatment effects on surrogate
outcomes predict treatment effects on patient-centred
outcomes.
Conclusions: Our results suggest that the FDA did
not use a consistent approach to address surrogates in
assessing the benefits and harms of drugs for COPD,
type 1 or 2 diabetes, glaucoma and osteoporosis. For
evaluating new drugs, patient-centred outcomes should
be chosen whenever possible. If the use of surrogate
outcomes is necessary, then a consistent approach is
important to review the evidence for surrogacy and
consider surrogate’s usage in the treatment and
population under study.
INTRODUCTION
A surrogate outcome is a biomarker or an
intermediate outcome that substitutes for
patient-centred outcomes, that is, outcomes
that patients notice and care about such as
survival, function, symptoms and
health-related quality of life.1 2 Because using
patient-centred outcomes in randomised
clinical trials (RCTs) may require a study that
is larger and takes longer, in certain disease
areas, surrogate outcomes are commonly
used as the primary outcomes in designing
RCTs, to save time, sample size and resources
to show a particular treatment effect size.3
For example, Gandhi et al4 found that, in 436
registered RCTs in type 1 or 2 diabetes, only
78 (18%) trials chose patient-centred out-
comes as primary outcomes. Most trials used
glycosylated haemoglobin to test the efﬁcacy
of diabetes drugs rather than assessing their
effects on outcomes that have direct impacts
on patients, such as cardiovascular events.
However, there are dangers in relying
entirely on surrogate outcomes for treatment
effect evidence.5 Two classic examples are
encainide and ﬂecainide, which were new
agents approved by the US Food and Drug
Administration (FDA) for suppressing ven-
tricular arrhythmias to reduce cardiovascular-
related death. Although these agents had an
effect on surrogate outcomes (arrhythmias),
a clinical trial conducted to evaluate their
effect on survival showed that they actually
increased the risk of death in patients.6
Strengths and limitations of this study
▪ This study is one of the first to examine how a
national policymaker, in this case, the US Food
and Drug Administration (FDA), handles surro-
gate outcomes when making regulatory
decisions.
▪ For four diseases, we reviewed all drug approvals
in 2003–2012. We reviewed, for each drug, the
documents of drug labels and medical reviews in
order to have a comprehensive assessment of
how the treatment effect evidence on surrogate
outcomes was considered by drug reviewers.
▪ We focused on only four chronic diseases and
reviewed what was documented by the FDA drug
reviews. This limits the generalisability of our
findings.
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A metaepidemiological study carried out by Ciani et al7
also found that a larger treatment effect is more often
observed in clinical trials using surrogates as primary
outcomes than in trials using patient-centred outcomes.
Thus, use of surrogate outcomes in RCTs does not
provide sufﬁcient clarity for understanding the actual
beneﬁts and harms for patients taking the drugs. This
poses a real challenge to the regulatory bodies and
health technology assessment agencies to make licensing
and coverage decisions for prescription drugs.
Although policymakers such as the US FDA commonly
face the challenges of relying on surrogate outcomes to
make decisions about prescription drug safety and
effectiveness, little is known about how such challenges
are addressed. The challenges include, ﬁrst, to properly
evaluate the evidence supporting the use of surrogate
outcomes (‘validity’).1 3 For example, the International
Conference on Harmonisation guidelines for the
conduct of clinical trials for the registration of drugs
(ICH-9) criteria describe a hierarchy of evidence for sur-
rogacy.8 The evidence for surrogacy may come from
pathophysiological studies suggesting the biological
plausibility of the association between surrogate out-
comes and patient-centred outcomes, or from observa-
tional studies demonstrating the association between
them. The highest level of evidence requires that RCTs
have shown that the treatment effects on surrogate out-
comes can predict the treatment effects on patient-
centred outcomes. Another challenge for regulatory
bodies is when the evidence supporting the use of drugs
includes primarily surrogate outcomes (eg, a difference
in the biomarker measures between treatment groups),
how one can properly make a clinical interpretation of
such evidence.
It is not clear if the FDA adopts a consistent approach
to the use of surrogate outcomes for drug approvals
across a spectrum of diseases. Our study aim was to
provide empirical evidence on how surrogate outcomes
are handled by the FDA. We reviewed the drug
approvals produced by the FDA for four diseases, from
2003 to 2012, to learn how often these approvals were
based on surrogate outcomes, and whether and how the
rationale for using surrogate outcomes was discussed.
METHODS
Selection of drug approvals
We used the Drugs@FDA website (http://www.
accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
to identify all drug approvals produced from January
2003 to December 2012 (n=1043), by the US FDA.
Drugs@FDA is an open access database for drug pro-
ducts approved by the FDA; it contains a drug approval
package, including prescribing information, approval
letters and FDA reviews such as medical, chemistry,
pharmacology and statistical reviews. These reviews
provide scientiﬁc analysis of a drug product and
explain the FDA’s thinking for the approval decision.
Two authors (TY and Y-JH), working independently,
screened the list to select the approvals that were eligible.
The inclusion criteria were drug approvals where the
drugs are indicated for the treatment of chronic
obstructive pulmonary disease (COPD), diabetes, glau-
coma or osteoporosis. We focused on these four diseases
because surrogate outcomes (lung function parameters
for COPD, blood sugar level for diabetes, intraocular
pressure (IOP) for glaucoma and bone mineral density
for osteoporosis, respectively) are commonly used as
primary outcomes in RCTs and all of them are ‘well
established’ surrogates according to the guidance docu-
ments issued by the FDA.9–12 We excluded the drugs
that are only indicated for a speciﬁc symptom related to
the diseases or indicated for a speciﬁc patient subpopu-
lation. Thus, we excluded a glaucoma drug that is indi-
cated as an adjunct to ab externo glaucoma surgery, a
diabetes drug approved for treating adult patients with
endogenous Cushing’s syndrome who have type 2 dia-
betes, and a drug treating diabetic peripheral neuro-
pathic pain. We also removed any duplicate records. If
there was a disagreement between the two authors about
including or excluding a drug approval, we resolved it
by discussion.
Data extraction
During the drug’s approval process, the FDA review
team critically evaluates different aspects of the drug’s
beneﬁts and harms, and produces review documents,
including the medical, chemistry, pharmacology and stat-
istical reviews, etc. For each included drug approval, we
retrieved the prescribing information and medical
reviews that were available on the Drug@FDA website.
We focused on medical reviews instead of other reviews
because the FDA medical reviews are, as we learned
during pilot-testing of data extraction, most likely the
review documents where the FDA reviewers address the
issue of outcome selection. In addition, the medical
review documents provide the FDA reviewers’ assessment
of clinical evidence that establishes the efﬁcacy and
safety of the drug.
We developed and pilot-tested a standardised form for
data extraction. Using the documents of prescribing
information and medical reviews, we extracted the infor-
mation on indications and the primary outcomes that
the indications were based on. If it was not clear what
outcomes the indications were based on, we reviewed
the outcomes reported in the clinical studies cited in
the prescribing information to make a judgment. We
then categorised these outcomes into a surrogate
outcome or a patient-centred outcome using the deﬁn-
ition mentioned previously. For each drug approved
based only on surrogates, we examined if the rationale
for using surrogate outcomes was discussed or not (yes/
no). We also assessed whether the surrogate was identi-
ﬁed as being based on the highest level of evidence for
surrogacy using the ICH-9 criteria. Finally, we examined
if the reviewers interpreted surrogate outcome results in
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RCTs, using metrics such as minimal important differ-
ence (MID)13 or a threshold that has been shown to be
linked to patient-centred outcomes. Two authors (TY
and Y-JH) independently reviewed all documents and
extracted the data. The discrepancies between authors
were resolved through discussion. We used descriptive
statistics to summarise our ﬁndings.
RESULTS
Sixty-eight of 1043 (7%) drug approvals were about
COPD, diabetes, glaucoma or osteoporosis, and 58 (58/
1043; 6%) of these were eligible for our study. The
reasons for exclusion of approvals are summarised in
ﬁgure 1. Of the 58 included approvals, 9 were for COPD
(16%), 26 (45%) for diabetes, 9 (16%) for glaucoma
and 14 (24%) for osteoporosis. For three of the four
examined conditions, the drug approvals were mostly
based only on a surrogate outcome (COPD (7/9
approvals were based only on a surrogate, 78%), dia-
betes (26/26 approvals, 100%) and glaucoma (9/9
approvals, 100%), see online supplementary table S1).
COPD drug approvals were primarily based on the
effects on improving lung function, with the exception
of two drug approvals (SPIRIVA HANDIHALER and
DALIRESP), which also examined COPD exacerbations.
All diabetes drug approvals reviewed were based on low-
ering blood sugar level and all glaucoma drug approvals
reviewed were based on lowering IOP. Most drug
approvals for osteoporosis (10/14; 71%) were based on
both, surrogate outcomes (bone mineral density) and
patient-centred outcome (fractures).
Among the drugs that were approved based only on
surrogates, 11 (11/44, 25%) discussed, in the medical
review, the rationale for using surrogate outcomes
to demonstrate drug efﬁcacy for regulatory approval
(table 1). For COPD drug approvals based on surrogates,
a medical review for one drug (TUDORZA PRESSAIR)
mentioned the limitations of using lung function and the
importance of evaluating patient-centred outcomes such
as COPD exacerbations. For glaucoma, the reviews for
three drugs (ALPHAGAN P, QOLIANA and LUMIGAN)
discussed the rationale for using change in IOP for drug
approval. These reviews mentioned the association
between high IOP and visual function loss but, did not
cite evidence from RCTs that an effect on IOP predicts
an effect on visual function. For diabetes, we found
that the reviews for seven drugs (APIDRA, SYMLIN,
EXUBERA, JANUVIA, JANUMET, VICTOZA and
BYDUREON) discussed the rationale for use of surrogates
and three of them (SYMLIN, VICTOZA and BYDUREON)
justiﬁed choosing glycaemic control as an outcome by
clearly stating the evidence that corresponds to the
highest level of evidence for surrogacy using the ICH-9
criteria. For example, in the review of VICTOZA, the
reviewer stated that “HbA1c has excellent reliability,
predicts several diabetes-speciﬁc complications, and pro-
vides the current basis for treatment decisions. Lowering
HbA1c reduces microvascular complications in patients
with type 1 and type 2 diabetes and possibly macrovascu-
lar complications in patients with type 1 diabetes.” They
cited evidence from two long-term RCTs in patients with
diabetes to justify the use of surrogates.14 15 We did not
observe a change over time from 2003 to 2012, as to what
type of outcomes the drug approvals were based on or
how they justiﬁed the use of surrogates.
Regarding the interpretation of surrogate outcome
results in RCTs, 13 reviews (13/44, 30%) discussed the
use of MID or threshold. We found that a review for one
drug in COPD (ARCAPTA NEOHALER) mentioned a
MID and reviews for 12 drugs in diabetes (AVANDARYL,
SYMLIN, DUETACT, EXUBERA, JANUVIA, BYETTA,
CYCLOSET, ONGLYZA, KOMBIGLYZE XR, VICTOZA,
TRADJENTA and BYDUREON) mentioned a threshold
(number of patients achieving the target haemoglobin
A1C level) that is linked to patient-centred outcomes.
We did not ﬁnd the discussion of MID or threshold in
the reviews for glaucoma and osteoporosis.
Figure 1 Review process.
COPD, Chronic obstructive
pulmonary disease; FDA, Food
and Drug Administration.
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Table 1 Rationale for using surrogate outcomes discussed in drug medical reviews (n=11)
Disease Drug name
Year
approved Rationale for using surrogate outcomes
The rationale is based on: ‘treatment
effects on the surrogate outcome
predict treatment effects on the
patient-centred outcome’ (highest level
of evidence using the International
Conference on Harmonisation
guidelines for the conduct of clinical
trials for the registration of drugs
(ICH-9) criteria for surrogacy)
Evidence cited to support the use of
surrogate outcome
Chronic
obstructive
pulmonary
disease (COPD)
TUDORZA
PRESSAIR
2012 “Overall, the committee’s view was that the
Applicant’s data for the primary end point of
trough forced expiratory volume in one
second (FEV1) demonstrated statistical
significance, and that these results were
clinically meaningful…Comments were
made that the results for other measures of
efficacy (eg, the St George’s Respiratory
Questionnaire (SGRQ) and COPD
exacerbations), while generally not
statistical significant, were nonetheless
trending in a direction to support the results
for the primary end point… Several
comments were made regarding the
limitations of FEV1-based end points and
the importance of evaluating patient-centred
outcomes.”
No None
Diabetes (type 1
or 2)
APIDRA 2004 “GHb (note: glycosylated haemoglobin)
results were reported as glycated
haemoglobin A1c (HbA1c) equivalents and
are directly traceable to the Diabetes
Control and Complications Trial (DCCT)
reference, for which the relationship
between mean BG (blood glucose)
(measured by HbA1c) and the risk for
vascular complications has been
established.”
Unclear Diabetes control and complications
trial29
Diabetes (type 1
or 2)
SYMLIN 2005 “FDA (note: Food and Drug Administration)
accepts reduction in HbA1c as a measure
of efficacy in trials of new antidiabetic
agents. This use of HbA1c as a surrogate
end point reflects the finding that long-term
reduction of HbA1c decreases the risk of
diabetic complications, particularly
retinopathy.”
Yes None
Continued
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Table 1 Continued
Disease Drug name
Year
approved Rationale for using surrogate outcomes
The rationale is based on: ‘treatment
effects on the surrogate outcome
predict treatment effects on the
patient-centred outcome’ (highest level
of evidence using the International
Conference on Harmonisation
guidelines for the conduct of clinical
trials for the registration of drugs
(ICH-9) criteria for surrogacy)
Evidence cited to support the use of
surrogate outcome
Diabetes (type 1
or 2)
EXUBERA 2006 “An ideal trial would use diabetic
complications as end points, but the trial
size and duration needed for use of such
end points would be very large. There is
some controversy about whether HbA1c is
truly a good marker of the risk for
complications of diabetes. However, the
correlation of HbA1c with risk for the
development of microvascular disease in
type 1 diabetics is well-established
( Jeffcoate 2004), and thus HbA1c is a
good surrogate end point for the trials of
inhaled insulin in type 1 diabetics.”
No Jeffcoate 200430
Diabetes (type 2) JANUVIA 2006 “HbA1c is generally considered the most
reliable surrogate of glycaemic control, and
ultimately predicts late chronic
complications of T2DM (type 2 diabetes
mellitus) microvascular and macrovascular,
as demonstrated in the Diabetes Control
and Complications Trial (DCCT) and the
United Kingdom Prospective Diabetes
Study (UKPDS).”
Unclear Diabetes control and complications trial
and UK Prospective diabetes study14 29
Diabetes (type 2) JANUMET 2007 “HbA1c is generally considered the most
reliable surrogate of glycaemic control, and
ultimately predicts late chronic
complications of T2DM (type 2 diabetes
mellitus) microvascular and macrovascular,
as demonstrated in the Diabetes Control
and Complications Trial (DCCT) and the
United Kingdom Prospective Diabetes
Study (UKPDS).”
Unclear Diabetes control and complications trial
and UK Prospective diabetes study14 29
Diabetes (type 2) VICTOZA 2010 “HbA1c has excellent reliability, predicts
several diabetes-specific complications and
provides the current basis for treatment
decisions (American Diabetes Association
Yes Diabetes control and complications trial,
UK Prospective diabetes study and
diabetes control and complications trial/
epidemiology of diabetes interventions
Continued
Yu
T,etal.BM
J
Open
2015;5:e007960.doi:10.1136/bm
jopen-2015-007960
5
O
p
e
n
A
c
c
e
s
s
group.bmj.com
 o
n
 February 18, 2016 - Published by 
http://bmjopen.bmj.com/
D
ow
nloaded from
 
Table 1 Continued
Disease Drug name
Year
approved Rationale for using surrogate outcomes
The rationale is based on: ‘treatment
effects on the surrogate outcome
predict treatment effects on the
patient-centred outcome’ (highest level
of evidence using the International
Conference on Harmonisation
guidelines for the conduct of clinical
trials for the registration of drugs
(ICH-9) criteria for surrogacy)
Evidence cited to support the use of
surrogate outcome
2008)… Lowering HbA1c reduces
microvascular complications in patients with
type 1 and type 2 diabetes (Diabetes
Control and Complications Trial Research
Group 1993, UK Prospective Diabetes
Study (UKPDS) Group 1998) and possibly
macrovascular complications in patients
with type 1 diabetes (Diabetes Control and
Complications Trial/Epidemiology of
Diabetes Interventions and Complications
(DCCT/EDIC) Study Research Group 2005).”
and complications (DCCT/EDIC)
study14 29
Diabetes (type 2) BYDUREON 2012 “HbA1c has excellent reliability, predicts
several diabetes-specific complications and
provides the current basis for treatment
decisions (American Diabetes Association
2006)…Lowering HbA1c reduces
microvascular complications in patients with
type 1 and type 2 diabetes (Diabetes
Control and Complications Trial Research
Group 1993, UK Prospective Diabetes
Study (UKPDS) Group 1998). There is
weaker evidence showing that lowering
HbA1c reduces macrovascular
complications in patients with type 1
diabetes (Diabetes Control and
Complications Trial/Epidemiology of
Diabetes Interventions and Complications
(DCCT/EDIC) Study Research Group 2005).”
Yes Diabetes control and complications trial,
UK Prospective diabetes study and
diabetes control and complications trial/
epidemiology of diabetes interventions
and complications (DCCT/EDIC)
study14 29
Glaucoma ALPHAGAN P 2005 “Elevated IOP (intraocular pressure)
presents a major risk factor in
glaucomatous field loss. The higher the
level of IOP, the greater the likelihood of
optic nerve damage and visual field loss.”
No None
Glaucoma QOLIANA 2006 “Elevated intraocular pressure is an
aetiological factor in glaucomatous cupping.
Higher intraocular pressure corresponds
Unclear None
Continued
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DISCUSSION
Our study ﬁndings suggest that the FDA did not use a
consistent approach to address surrogate outcomes
when reviewing the drug approvals included in this
study. In diseases such as COPD, diabetes and glaucoma,
we found that RCT evidence relying on surrogate out-
comes forms the basis for FDA drug approvals. But for
osteoporosis, treatment effects on the surrogate
outcome (bone mineral density) and the patient-centred
outcome (fractures) were often examined together
when regulatory decisions were made. In addition, the
rationale for using surrogate outcomes for drug approval
was not always discussed. If it was discussed, drug
approvals for diabetes were more likely than drug
approvals for the other examined conditions to contain
a discussion of RCT evidence demonstrating that treat-
ment effects on surrogate outcomes (blood sugar level)
predict treatment effects on patient-centred outcomes
(macrovascular or microvascular events).
This study also demonstrates that the FDA regulatory
pathway for certain diseases still relies heavily on surro-
gate outcomes. Similarly, a recent survey of prescription
drugs conducted by Downing et al16 found that surrogate
outcomes were used as the primary outcomes in about
50% of pivotal trials for FDA regulatory approval. The
actual treatment effect of many drugs on patients is thus
left to be extrapolated from treatment effect on surro-
gates by clinicians themselves who prescribe the drugs
and by patients themselves who take the drugs. For
example, most drugs for diabetes are only indicated for
‘glycaemic control’ rather than indicated for lowering
the risk of patient-centred outcomes such as stroke or
amputation. To make an extrapolation of the treatment
effect clinically, a MID or threshold is often deﬁned. In
this case, the target level for glycaemic control is set as
haemoglobin A1C <7% in adult patients with type 2 dia-
betes mellitus,17 which is a level of haemoglobin A1C
that has been linked to a lower risk of microvascular or
macrovascular events. However, we should be cautious
when using a threshold of this kind. The target level of
surrogates may not hold constant across different drugs
(drug classes) or different patient groups,18 19 since sur-
rogates may have a continuous (instead of dichotomous)
and other non-linear associations with the correspond-
ing patient-centred outcomes.20 Ideally, we should have
treatment evidence on outcomes that are directly rele-
vant to patients. RCTs should provide us direct evidence
on how much of an impact the drugs have on patient-
centred outcomes. Decision-makers can then be better
informed of the beneﬁts and harms that the drugs cause
to patients.
For making market authorisation or coverage deci-
sions, we suggest that policymakers should consider pri-
marily the evidence on patient-centred outcomes. Some
may argue that for some diseases it is not always feasible
to design and implement RCTs assessing patient-centred
outcomes. In fact, this could be the argument that
would be made for three diseases examined in this study
Ta
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(COPD, diabetes and glaucoma), for which the FDA
allows relying on surrogate outcomes to approve the
drugs. In such situations, when evidence on patient-
centred outcomes for a drug is lacking, drug reviews
should properly consider the validity of using surrogate
outcomes in the speciﬁc drug and population of inter-
est. In our survey, we found the rationale for using surro-
gate outcomes for drug approval was not often discussed
in the FDA medical reviews. Even if the rationale was
given, certain reviews were not clear about the role of
surrogate outcomes and considered them appropriate
for RCTs based solely on the assertion that they are the
risk factors for patient-centred outcomes. Some reviews
for diabetes drugs considered evidence from RCTs dem-
onstrating that the effect on surrogates can predict the
effect on patient-centred outcomes but such evidence
was from a limited number of trials and was not exam-
ined in a systematic way.
We reviewed published guidance21–23 on surrogate
outcomes and make the following suggestions for drug
reviewers (or any decision-makers who need to weigh
the beneﬁts and harms of treatments) to properly
handle surrogate outcomes:
1. Evidence for surrogacy should be based on RCTs
evaluating whether the treatment effect on surrogates
predicts treatment effect on patient-centred
outcomes
Surrogate outcomes are used in RCTs because they
can be an indicator or intermediate variable in the
disease process and can substitute for patient-centred
outcomes. There is often good evidence from epidemio-
logical studies that demonstrate the association between
both outcomes. However, to formally validate a surro-
gate outcome, it is necessary to have evidence from
RCTs assessing whether the treatment effect on surro-
gates consistently predicts the treatment effect on
patient-centred outcomes. Prentice developed a statis-
tical criterion for evaluating surrogate outcomes in
trials,24 which requires that surrogate outcomes fully
capture the treatment effect on patient-centred out-
comes. However, this criterion is seldom met in
practice.
Another statistical approach to validate surrogate out-
comes is using data from multiple RCTs that assess surro-
gate outcomes and patient-centred outcomes.23 One can
build a multilevel model to ﬁt data from multiple trials
and calculate a trial-level and an individual-level associ-
ation between treatment effects on both outcomes, or
one can calculate the ‘surrogate threshold effect’ to
evaluate the evidence for surrogacy.23 A detailed discus-
sion of statistical methods for validating surrogate out-
comes is out of scope for this article but some
references are provided here.23–25
2. The evidence for surrogacy may be context-speciﬁc
The validity of surrogate outcomes can potentially vary
by disease, drug (or drug classes) and subpopulation
because surrogate outcomes may not mediate the
disease pathway in the same way across different
contexts.18 19 Additionally, drugs can cause beneﬁts or
harms to patients through the effect that is independent
of surrogate outcomes.5 Thus, when evaluating existing
evidence for surrogacy, we suggest conducting systematic
reviews of RCTs and trying to investigate the heterogen-
eity of the evidence for surrogacy, and consideration of
all important outcomes. For reviewing a new drug, it is
probably not common that the validity of the surrogates
has been already established in the speciﬁc treatment or
population under review, so an extrapolation of the
treatment effect is inevitable. Nonetheless, it is import-
ant for drug reviewers to recognise the limitations of
making such extrapolations.
3. The role of postmarketing studies should be empha-
sised if surrogate outcomes are used as a basis for
drug approvals
One way to alleviate the threats of relying on surrogate
outcomes for drug approval is by requiring long-term
postmarketing studies.26 Rosiglitazone, for example, was
approved by the FDA for effectively controlling the
blood sugar level in patients with diabetes. However,
later meta-analyses have suggested that rosiglitazone is
associated with an unexpected higher risk for cardiovas-
cular events.27 Accordingly, the FDA now requires drug
companies manufacturing diabetes drugs to provide
data on cardiovascular outcomes and to continue moni-
toring the drug safety in postmarketing studies, in
certain circumstances.28 As long as the drugs are
approved based on surrogate outcomes without knowing
their effect on patient-centred outcomes, we will never
be certain of their actual beneﬁcial or harmful effects
on patients. We emphasise the importance of conduct-
ing long-term safety studies.16 28
Limitation of our survey
Our study only focused on the surrogate outcomes used
for drug efﬁcacy and did not address surrogate out-
comes that substitute for harms. Harmful events are
often rare and may take a longer time to develop so that
regulatory agencies may be even more dependent on
surrogate outcomes for harms regardless of their validity
and will require more data beyond RCTs, such as large
and long-term postmarketing studies, to assess the
harms. We reviewed four diseases where surrogate out-
comes are commonly used but did not review diseases
such as cancers or HIV, where the use of surrogate out-
comes is also prevalent. There may be considerations
with regard to the lack of treatment alternatives, so the
use of surrogate outcomes is necessary for cancers or
HIV drugs to accelerate the regulatory approval
process.1 We did not evaluate the new drug applications
that were declined by the FDA because these documents
are not publicly available. There may be more explicit
analysis of surrogate outcomes in those documents. We
focused on medical reviews of the FDA drug approval
process since we found that this is where a discussion of
surrogate outcomes would most likely be documented,
but there is the possibility that it was mentioned
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elsewhere in the FDA reviews. Finally, not documenting
the rationale for use of surrogate outcomes does not
mean that the FDA reviewers did not take it into
account when making decisions. However, a documen-
ted discussion of the evidence will certainly increase the
transparency of the process in which regulatory bodies
consider surrogate outcomes for drug approvals.
CONCLUSIONS
Our survey ﬁndings suggest that, for three of the dis-
eases examined (COPD, diabetes and glaucoma), drugs
are approved based on their treatment effects on surro-
gate outcomes, but that the FDA does not use a consist-
ent approach for surrogates in order to evaluate these
drug applications. This makes it difﬁcult to assess and
interpret their actual clinical effects on outcomes
important to patients. For evaluating new drugs, patient-
centred outcomes should be used whenever possible. If
the use of surrogate outcomes is needed, assessing the
validity of surrogate outcomes and considering the sur-
rogate’s usage in the treatment and population under
study is necessary to inform a drug evaluation.
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